NeuroPace (NPCE) Announces Strategic CFO Transition

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period.

“NeuroPace is pleased to have a financial leader of Patrick’s caliber join the team at a time of such significant opportunity for our RNS System and critical point in our growth trajectory,” said Joel Becker, President and CEO. “He brings a strong track record of success helping medical device companies scale and grow, and his financial leadership will be a tremendous asset as we continue to expand access to the RNS System. His experience across commercial-stage and high-growth organizations will be valuable as we focus on driving long-term value.”

Mr. Becker added, “On behalf of the NeuroPace board and employees, I would like to acknowledge and thank Rebecca for her dedication to NeuroPace and for all that she has done for the Company and for our patients over her 25-year tenure. Rebecca has been instrumental in building the foundation of NeuroPace and helping us reach key milestones, and her financial leadership has created significant value for NeuroPace over the years. We are deeply grateful for Rebecca’s commitment to the Company’s mission throughout her time with us, and we wish her continued success in her future endeavors.”

Mr. Williams joins NeuroPace with over 25 years of financial and operational management experience with public medical device companies. Mr. Williams most recently served as Chief Financial Officer at STAAR Surgical. Prior to STAAR, he initially served as the Chief Financial Officer of Sientra before transitioning to the General Manager of the miraDry® business unit. Prior to Sientra, he was Chief Financial Officer of ZELTIQ, a medical device company that was acquired in 2017. Mr. Williams has also served as Vice President at NuVasive, a spine medical device company, in strategy, finance and investor relations roles.

Mr. Williams stated, “I am incredibly excited to join NeuroPace at such a pivotal time. The Company is just beginning to tap into a significant market opportunity, with the potential to bring life-changing benefits to the approximately 1.2 million U.S. patients living with drug resistant epilepsy. I believe the RNS System is uniquely positioned to become the standard of care in both our existing and anticipated future expanded indications, and I am energized by the Company’s commitment to product and data development to drive better patient outcomes and support greater utilization. I look forward to helping expand access to and utilization of this breakthrough therapy and to advancing NeuroPace’s mission through my experience building and scaling innovative medical device businesses.”

You May Also Be Interested In

• Brown-Forman CEO Lawson Whiting to retire after nearly 30 years
• Tavia and Vita Inclinata sign LOI for $450M SPAC merger
• Astrana Health names two executives to expand leadership team